1. Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial
- Author
-
Panos Deloukas, Milan Vukic, Ilias Smyrnioudis, Charalampia Amerikanou, Lucia Cesarini, George Dedoussis, Mladen Bjelan, Iraklis Varlamis, M. Pilar Francino, Francisco J. Roig, Stavroula Kanoni, Beatriz Soriano, Giuseppe D'Auria, Maria Giovanna Trivella, Sofia Mouchti, John Victor Lamont, Aimo Kannt, Maria Halabalaki, Milica Medic-Stojanoska, Andriana C. Kaliora, Carlos Llorens, Natasa Milic, Miriam Marascio, Fernando Marascio, Jonica Campolo, Angela Barone, Sophie Visvikis-Siest, Aristea Gioxari, Rajarshi Banerjee, Amalia Gastaldelli, Eleni V Mikropoulou, María José Gosalbes, Stefan Stojanoski, Maria G. Stathopoulou, Harokopio University of Athens, William Harvey Research Institute, Barts and the London Medical School, University of Novi Sad, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana [Espagne] (FISABIO), CIBER de Epidemiología y Salud Pública (CIBERESP), Interactions Gène-Environnement en Physiopathologie Cardio-Vasculaire (IGE-PCV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Biotechvana [Valencia, Spain], National and Kapodistrian University of Athens (NKUA), SANOFI (Research and Development), Research and Development, Goethe-Universität Frankfurt am Main, Randox Laboratories Limited [Crumlin, Irlande du Nord], Universidad San Jorge, Queen Mary University of London (QMUL), European Commission, European Research Council, and Publica
- Subjects
Male ,0301 basic medicine ,NAFLD/NASH ,[SDV]Life Sciences [q-bio] ,MathematicsofComputing_GENERAL ,Gut flora ,Gastroenterology ,Body Mass Index ,law.invention ,Placebos ,metabolomics ,Liver disease ,Randomized controlled trial ,Non-alcoholic Fatty Liver Disease ,Fibrosis ,law ,Nonalcoholic fatty liver disease ,microbiota dysbiosis ,ComputingMilieux_MISCELLANEOUS ,Greece ,biology ,Mastic Resin ,Mastiha ,NASH ,TheoryofComputation_GENERAL ,Middle Aged ,3. Good health ,Italy ,Liver ,Female ,Serbia ,MRI ,Biotechnology ,Adult ,medicine.medical_specialty ,Placebo ,03 medical and health sciences ,Double-Blind Method ,NAFLD ,Internal medicine ,medicine ,Humans ,Obesity ,Aged ,030109 nutrition & dietetics ,business.industry ,medicine.disease ,biology.organism_classification ,Gastrointestinal Microbiome ,Clinical trial ,030104 developmental biology ,Dietary Supplements ,Dysbiosis ,ComputingMilieux_COMPUTERSANDSOCIETY ,business ,Food Science - Abstract
On behalf of MAST4HEALTH consortium: et al., [Scope]: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with poor therapeutic strategies. Mastiha possesses antioxidant/anti-inflammatory and lipid-lowering properties. The authors investigate the effectiveness of Mastiha as a nonpharmacological intervention in NAFLD., [Methods and Results]: Ninety-eight patients with NAFLD in three countries (Greece, Italy, Serbia) are randomly allocated to either Mastiha or Placebo for 6 months, as part of a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. The authors assess NAFLD severity via magnetic resonance imaging (MRI) scanning and LiverMultiScan technique and evaluate the effectiveness of Mastiha through medical, anthropometric, biochemical, metabolomic, and microbiota assessment. Mastiha is not superior to Placebo on changes in iron-corrected T1 (cT1) and Liver Inflammation Fibrosis score (LIF) in entire patient population; however, after BMI stratification (BMI ≤ 35 kg m-2 and BMI > 35 kg m-2), severely obese patients show an improvement in cT1 and LIF in Mastiha versus Placebo. Mastiha increases dissimilarity of gut microbiota, as shown by the Bray-Curtis index, downregulates Flavonifractor, a known inflammatory taxon and decreases Lysophosphatidylcholines-(LysoPC) 18:1, Lysophosphatidylethanolamines-(LysoPE) 18:1, and cholic acid compared to Placebo., [Conclusion]: Mastiha supplementation improves microbiota dysbiosis and lipid metabolite levels in patients with NAFLD, although it reduces parameters of liver inflammation/fibrosis only in severely obese patients., This project was funded by the European Union’s Horizon 2020 researchand innovation program MAST4HEALTH under the Marie Skłodowska-Curie grant agreement no. 691042.
- Published
- 2021
- Full Text
- View/download PDF